China's medical products administrator granted full approval to Everest Medicines' (HKG:1952) delayed-release corticosteroid budesonide for primary immunoglobulin A nephropathy, according to a Wednesday filing with the Hong Kong bourse.
The drug, branded Nefecon, is indicated for adults at risk for kidney malfunction progression regardless of proteinuria or protein content in urine, the filing said.
Nefecon showed a reduction in urine protein-creatinine ratio, while kidney function decline slowed by 66% among Chinese phase 3 trial participants, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.